Kidney Cancer Drugs Market Growth, Size, Trends Analysis - By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Kidney Cancer Drugs Market Introduction and Overview

According to SPER market research, 'Kidney Cancer Drugs Market Size- By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Kidney Cancer Drugs Market is predicted to reach 11.56 billion by 2034 with a CAGR of 5.83%.

Kidney cancer drugs are medications and therapies used to treat kidney cancer, also referred to as renal cell carcinoma (RCC) or renal cell adenocarcinoma. These medications are intended to target cancer cells, slow their growth, and/or boost the body's immune response against cancer.

Restraints:The lack of appropriate regulatory standards for medicine prescriptions, as well as a preference for low-cost generic kidney cancer treatments, are anticipated to stymie the worldwide drug industry. Furthermore, medications that destroy cancer cells are toxic to healthy cells in the body. This produces many negative effects in patients, the most common of which are gastrointestinal problems, hair loss, tiredness, and skin illnesses. As a result, the negative aspects of kidney cancer medications are impeding market growth.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered Active Biotech AB, Amgen, Inc, Astellas Pharma Inc, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Exelixis, Inc, F. Hoffmann-La Roche Ltd, Genentech, Inc, GSK plc, Helsinn Healthcare SA, Johnson & Johnson Services, Inc, Merck & Co., Inc.

Kidney Cancer Drugs Market Segmentation:

By Cancer Type: Based on the Cancer Type, Global Kidney Cancer Drugs Market is segmented as; Renal cell carcinoma, Transitional cell cancer, Wilms tumor, Renal sarcoma.

By Therapy: Based on the Therapy, Global Kidney Cancer Drugs Market is segmented as; Targeted therapy, Immunotherapy, Chemotherapy, Other therapies.

By Drug Class: Based on the Drug Class, Global Kidney Cancer Drugs Market is segmented as; Angiogenesis inhibitors, Monoclonal antibodies, mTOR inhibitors, Cytokine immunotherapy, Other drug classes.

By Route of Administration: Based on the Route of Administration, Global Kidney Cancer Drugs Market is segmented as; Oral, Intravenous, Subcutaneous.

By Distribution Channel: Based on the Distribution Channel, Global Kidney Cancer Drugs Market is segmented as; Hospital pharmacy, Brick and mortar, E-commerce.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: PHAR2504

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Kidney Cancer Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Kidney Cancer Drugs Market

7. Global Kidney Cancer Drugs Market, By Cancer Type (USD Million) 2021-2034

7.1. Renal cell carcinoma (RCC)
7.2. Transitional cell cancer
7.3. Wilms tumor
7.4. Renal sarcoma

8. Global Kidney Cancer Drugs Market, By Therapy (USD Million) 2021-2034

8.1. Targeted therapy
8.2. Immunotherapy
8.3. Chemotherapy
8.4. Other therapies

9. Global Kidney Cancer Drugs Market, By Drug Class (USD Million) 2021-2034

9.1. Angiogenesis inhibitors
9.2. Monoclonal antibodies
9.3. mTOR inhibitors
9.4. Cytokine immunotherapy (IL-2)
9.5. Other drug classes

10. Global Kidney Cancer Drugs Market, By Route of Administration (USD Million) 2021-2034

10.1. Oral
10.2. Intravenous
10.3. Subcutaneous

11. Global Kidney Cancer Drugs Market, By Distribution Channel (USD Million) 2021-2034

11.1. Hospital pharmacy
11.2. Brick and mortar
11.3. E-commerce

12. Global Kidney Cancer Drugs Market, (USD Million) 2021-2034

12.1. Global Kidney Cancer Drugs Market Size and Market Share

13. Global Kidney Cancer Drugs Market, By Region, (USD Million) 2021-2034

13.1. Asia-Pacific
- 13.1.1. Australia
- 13.1.2. China
- 13.1.3. India
- 13.1.4. Japan
- 13.1.5. South Korea
- 13.1.6. Rest of Asia-Pacific
13.2. Europe
- 13.2.1. France
- 13.2.2. Germany
- 13.2.3. Italy
- 13.2.4. Spain
- 13.2.5. United Kingdom
- 13.2.6. Rest of Europe
13.3. Middle East and Africa
- 13.3.1. Kingdom of Saudi Arabia
- 13.3.2. United Arab Emirates
- 13.3.3. Qatar
- 13.3.4. South Africa
- 13.3.5. Egypt
- 13.3.6. Morocco
- 13.3.7. Nigeria
- 13.3.8. Rest of Middle-East and Africa
13.4. North America
- 13.4.1. Canada
- 13.4.2. Mexico
- 13.4.3. United States
13.5. Latin America
- 13.5.1. Argentina
- 13.5.2. Brazil
- 13.5.3. Rest of Latin America

14. Company Profile

14.1. Active Biotech AB
- 14.1.1. Company details
- 14.1.2. Financial outlook
- 14.1.3. Product summary
- 14.1.4. Recent developments
14.2. Amgen, Inc
- 14.2.1. Company details
- 14.2.2. Financial outlook
- 14.2.3. Product summary
- 14.2.4. Recent developments
14.3. Astellas Pharma Inc
- 14.3.1. Company details
- 14.3.2. Financial outlook
- 14.3.3. Product summary
- 14.3.4. Recent developments
14.4. AstraZeneca PLC
- 14.4.1. Company details
- 14.4.2. Financial outlook
- 14.4.3. Product summary
- 14.4.4. Recent developments
14.5. Bayer AG
- 14.5.1. Company details
- 14.5.2. Financial outlook
- 14.5.3. Product summary
- 14.5.4. Recent developments
14.6. Bristol-Myers Squibb Company
- 14.6.1. Company details
- 14.6.2. Financial outlook
- 14.6.3. Product summary
- 14.6.4. Recent developments
14.7. Eisai Co., Ltd
- 14.7.1. Company details
- 14.7.2. Financial outlook
- 14.7.3. Product summary
- 14.7.4. Recent developments
14.8. Exelixis, Inc
- 14.8.1. Company details
- 14.8.2. Financial outlook
- 14.8.3. Product summary
- 14.8.4. Recent developments
14.9. F. Hoffmann-La Roche Ltd
- 14.9.1. Company details
- 14.9.2. Financial outlook
- 14.9.3. Product summary
- 14.9.4. Recent developments
14.10. Genentech, Inc
- 14.10.1. Company details
- 14.10.2. Financial outlook
- 14.10.3. Product summary
- 14.10.4. Recent developments
14.11. GSK plc
- 14.11.1. Company details
- 14.11.2. Financial outlook
- 14.11.3. Product summary
- 14.11.4. Recent developments
14.12. Helsinn Healthcare SA
- 14.12.1. Company details
- 14.12.2. Financial outlook
- 14.12.3. Product summary
- 14.12.4. Recent developments
14.13. Johnson & Johnson Services, Inc
- 14.13.1. Company details
- 14.13.2. Financial outlook
- 14.13.3. Product summary
- 14.13.4. Recent developments
14.14. Merck & Co., Inc
- 14.14.1. Company details
- 14.14.2. Financial outlook
- 14.14.3. Product summary
- 14.14.4. Recent developments
14.15. Others